Loading stock data…
MESO
$15.74+0.07 (+0.45%)
Market ClosedLast close May 1
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Mesoblast Limited in the Healthcare sector is trading at $15.74. The stock is currently 27% below its 52-week high of $21.50, remaining 3.7% below its 200-day moving average. Technical signals show neutral RSI of 63 and bullish MACD crossover, explaining why MESO maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 63) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$15.74
Potential Upside
5%
Whystock Fair Value$16.53
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$35.00+122.4%
Range$35.00 – $35.00
Fundamentals
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.01B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.82
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-16.42%
Volume
Today's trading volume
146,776
Recent News
How Completion Of RMAT Phase 3 Enrollment At Mesoblast (ASX:MSB) Has Changed Its Investment Story
Mesoblast Limited recently announced it has completed patient recruitment for its pivotal Phase 3 trial of rexlemestrocel-L in chronic low back pain due to degenerative disc disease, a placebo-controlled study following at least 300 patients for 12 months. This milestone moves the program closer to potential FDA filing for rexlemestrocel-L, which holds RMAT designation in a multi-million patient indication closely linked to prescription opioid use. We’ll now examine how reaching full...
ASX Penny Stocks To Watch In April 2026
As the Australian market faces its seventh consecutive day in the red, with inflation expected to spike to nearly three-year highs, investor sentiment has turned bearish. Despite these challenging conditions, penny stocks remain a relevant investment area for those seeking growth opportunities in smaller or newer companies. While the term 'penny stock' might seem outdated, these stocks can offer significant potential when backed by strong financials, and we've identified three such examples...
ASX Growth Companies With High Insider Ownership In April 2026
As Australian shares enter their seventh consecutive day in the red, market sentiment has shifted into bearish territory amid concerns over rising inflation and potential interest rate hikes. In this challenging environment, growth companies with high insider ownership can be appealing as they often indicate strong confidence from those who know the business best.
Assessing Mesoblast’s Valuation After Recent Share Price Weakness And Conflicting Growth Signals
Mesoblast share move and recent return profile Mesoblast (ASX:MSB) recently closed at A$2.15, catching attention after a mixed set of short and longer term returns, including a 0.5% gain over the past day and a 6.5% decline over the past week. See our latest analysis for Mesoblast. While the 1 day share price return was slightly positive, the 7 day and year to date share price returns have been weak. However, the 1 year and 3 year total shareholder returns remain firmly positive, suggesting...
Mesoblast Ltd (MESO): Secure Exclusive Rights to a Vital Platform
Mesoblast Ltd (NASDAQ:MESO) is among the best Australian stocks to buy in 2026. On April 14, Mesoblast Ltd (NASDAQ:MESO) announced that it has secured exclusive global rights to a patented technology platform from Mayo Clinic. This platform uses chimeric antigen receptors, and it helps improve the performance of mesenchymal lineage stromal cell (MSC) therapeutic products. […]